Verastem Presents Avutometinib And Defactinib Combination Program Updates At The 5th Annual RAS-Targeted Drug Development Summit
Portfolio Pulse from Benzinga Newsdesk
Verastem Oncology (NASDAQ:VSTM) has presented updates on its avutometinib and defactinib programs at the 5th Annual RAS-Targeted Drug Development Summit. The updates include clinical trial results showing an overall response rate of 42% in patients with low grade serous ovarian cancer. The company's FRAME study, which evaluates the combination of avutometinib and defactinib in patients with advanced solid tumors, continues to provide proof-of-concept supporting Breakthrough Therapy Designation for the combination.
September 28, 2023 | 6:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Verastem's updates on its avutometinib and defactinib programs, including promising clinical trial results, could potentially boost investor confidence and positively impact its stock price.
The promising results from Verastem's clinical trials on its avutometinib and defactinib programs could potentially lead to increased investor confidence in the company's ability to develop effective cancer treatments. This could result in increased demand for the company's stock, leading to a potential increase in its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100